These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16320055)

  • 21. Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
    Voigt W; Pickan V; Pfeiffer C; Mueller T; Simon H; Arnold D
    Onkologie; 2005 Oct; 28(10):482-8. PubMed ID: 16160394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
    Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
    Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
    De Cesare M; Lauricella C; Veronese SM; Cominetti D; Pisano C; Zunino F; Zaffaroni N; Zuco V
    Clin Cancer Res; 2014 Feb; 20(4):995-1006. PubMed ID: 24327272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
    Moosmann N; Heinemann V
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):319-29. PubMed ID: 18366281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.
    Ekblad L; Johnsson A
    Anticancer Res; 2012 Mar; 32(3):783-6. PubMed ID: 22399593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts.
    Deberne M; Levy A; Mondini M; Dessen P; Vivet S; Supiramaniam A; Vozenin MC; Deutsch E
    Anticancer Drugs; 2013 Jul; 24(6):599-608. PubMed ID: 23698251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
    Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells.
    Yip WL; Weyergang A; Berg K; Tønnesen HH; Selbo PK
    Mol Pharm; 2007; 4(2):241-51. PubMed ID: 17263556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
    Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
    Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
    Tonra JR; Corcoran E; Deevi DS; Steiner P; Kearney J; Li H; Ludwig DL; Zhu Z; Witte L; Surguladze D; Hicklin DJ
    Anticancer Res; 2009 Jun; 29(6):1999-2007. PubMed ID: 19528458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
    Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
    Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.
    Sung FL; Poon TC; Hui EP; Ma BB; Liong E; To KF; Huang DP; Chan AT
    In Vivo; 2005; 19(1):237-45. PubMed ID: 15796181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
    Aerts HJ; Dubois L; Hackeng TM; Straathof R; Chiu RK; Lieuwes NG; Jutten B; Weppler SA; Lammering G; Wouters BG; Lambin P
    Radiother Oncol; 2007 Jun; 83(3):326-32. PubMed ID: 17531336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.